anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Itraconazole oral solution should not be used in patients with evidence of ventricular dysfunction unless the benefit clearly outweighs the risk. For patients with risk factors for congestive heart failure, physicians should carefully review the risks and benefits of itraconazole therapy. These risk factors include cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disease; and renal failure and other edematous disorders. Such patients should be informed of the signs and symptoms of CHF, should be treated with caution, and should be monitored for signs and symptoms of CHF during treatment. If signs or symptoms of CHF appear during administration of itraconazole oral solution, monitor carefully and consider other treatment alternatives which may include discontinuation of itraconazole oral solution administration. 

Itraconazole has been shown to have a negative inotropic effect. When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later. 

Itraconazole oral solution has been associated with reports of congestive heart failure. In post-marketing experience, heart failure was more frequently reported in patients receiving a total daily dose of 400 mg although there were also cases reported among those receiving lower total daily doses. 

Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers. Therefore, caution should be used when co-administering itraconazole and calcium channel blockers due to an increased risk of CHF. Concomitant administration of itraconazole and felodipine or nisoldipine is contraindicated. 

Cases of CHF, peripheral edema, and pulmonary edema have been reported in the post-marketing period among patients being treated for onychomycosis and/or systemic fungal infections. (See CONTRAINDICATIONS, CLINICAL PHARMACOLOGY: Special Populations, PRECAUTIONS: Drug Interactions, and ADVERSE REACTIONS: Postmarketing Experience for more information.)
BACKGROUND: Respiratory viral infections are common in febrile infants ≤90 days. However, the detection of viruses other than enterovirus in the blood and cerebrospinal fluid (CSF) of young infants is not well defined. We sought to quantify the occurrence of respiratory viruses in the blood and CSF of febrile infants ≤90 days.
METHODS: We conducted a nested cohort study examining plasma and CSF samples from febrile infants 15-90 days via rtPCR. The samples were tested for respiratory viruses (respiratory syncytial virus, influenza, enterovirus, parechovirus, adenovirus, bocavirus). Clinical and laboratory data were also collected to determine the presence of serious bacterial infections (SBI).
RESULTS: Twenty-four percent (30 of 126) of infants had plasma/CSF specimens positive for a respiratory virus. Enterovirus and parechovirus were the most commonly detected respiratory viruses. Viral positivity was highest in plasma samples at 25% (27 of 107) compared with CSF samples at 15% (nine of 62). SBIs (specifically urinary tract infections) were less common in infants with a sample positive for a respiratory virus compared to those without a virus detected (3% vs. 26%, p = 0.008).
CONCLUSIONS: Our findings support the use of molecular diagnostics to include the identification of parechovirus in addition to enterovirus in febrile infants ≤90 days. Additionally, these data support the utilization of blood specimens to diagnose enterovirus and parechovirus infections in febrile infants ≤90 days.
<P>PROBLEM TO BE SOLVED: To provide an inserted fused body which comprises a human protein synthesis inhibitor and a human physiologically active substance inserted thereinto to realize a more purposive structure while maintaining the function of each conjugated protein; and a medicine composition containing the inserted fused body as an effective component.  <P>SOLUTION: The inserted fused body having the functions of RNase 1 and bFGF is prepared by inserting a human bFGF, i.e. a human physiologically active substance, into the primary sequence corresponding to the loop position of a human RNase 1, i.e. a human protein synthesis inhibitor, to be expressed in a host cell. The inserted fused body exhibits a cytotoxic activity selectively to a cell highly expressing an FGF receptor of cancer cells, etc.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Major abdominal surgeries may be followed by postoperative pulmonary complications (PPCs). These complications are common and can cause significant morbidity and mortality.

Major operations are followed by acute respiratory insufficiency (RI) in 3%-27.4%, which causes prolonged hospital stay, high patient costs, high mortality rate and lower survival rates. The most crucial pulmonary postoperative complication is the prolonged mechanical ventilation and difficult weaning.The rHGH is a synthetic metabolic hormone which improves synthesis of protein, corrects hypoalbumenia, reverses negative nitrogen balance, improves patient nutrition, improves wound healing and promotes recovery of respiratory muscle function. When used for weaning from mechanical ventilation, rHGH reducess the duration of mechanical ventilation time, ICU admission period, incidence of VAP \& ICU mortality. Felbinger et al reported a case of prolonged ventilation with failure of weaning after 42 days; the patient received subcutaneous rHGH (0.3 IU/kg/day) for 20 days in addition to intensive care standard management. They reported improvement of protein metabolism in addition to improvement of respiratory muscle strength, the patient was weaned successfully on the 75th postoperative day.this study assumes a hypothesis that rHGH would help weaning from mechanically ventilated tracheostomized patients.
<P>PROBLEM TO BE SOLVED: To provide a hair follicle-regenerating system that contains activated hair papilla cells and activated epithelial cells at a rate that is suitable for regeneration of hair follicle.  <P>SOLUTION: The subject composition for regenerating hair follicles comprises hair papilla cells and epithelial cells, and has a cell number ratio of the hair papilla cells to the epithelial cells of 1/10 to 10/1. In a preferred embodiment, the composition contains hair papilla cells and epithelial cells and is used for regenerating the hair follicles. The composition comprises the epithelial cells and the hair papilla cells. A preparation of the hair papilla cells is obtained by treating a dermal tissue fraction prepared by removing epithelial tissue from dermal tissue with collagen to prepare a cell suspension after killing the hair follicle epithelial cells, then the composition for regenerating hair follicles comprising the hair papilla cells and the epithelial cells at a cell cumber ratio of 1/10 to 10/1 is obtained.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:An antitumor agent containing a limitedly decomposed fragment of the fifth component of human complement (C5) as an active constituent. CONSTITUTION:An antitumor agent containing a limitedly decomposed fragment (the bond between the 74th-75th arginines from the amino terminal of alpha-chain and the other amino acid of C5 is limitedly decomposed in the course of activation of the complement, and C5 is converted into C5a having 8,200 molecular weight and C5b having 190,000 molecular weight. One arginine residue is removed from the carboxyl end groups of C5a to give C5adesArg. The fragment means the above-mentioned C5a, C5b, C5adesArg or a complex thereof with other complement components) of the fifth component of human complement (C5; a protein, contained in blood serum at about 75mug/ml ratio, and having about 200,000 molecular weight, alpha-chain having 120,000 molecular weight and beta-chain having 8,000 molecular weight corsslinked through S-S bonds) as an active constituent. The method of administration and dosage form are not particularly limited, but for example, intravenous administration may be cited. The fragement is present in a carrier in 0.5-500mug/ml concentration, and the dose thereof is 5mug-5mg/kg/time.
Our overall goal is to determine the safety and efficacy of testosterone supplementation as an adjunct to traditional rehabilitation therapy on health outcomes in deconditioned older men. Specifically, we will conduct a randomized, placebo-controlled trial to test the hypothesis that supplementation with testosterone improves rehabilitation outcomes in deconditioned older men. We will use objective validated measures (i.e., FIM, muscle strength) to assess health outcomes.

We will begin enrolling subjects within three months of receipt of funding, and study 60 subjects (30 in each group) within 24 months. All subjects will undergo follow-up evaluation 6 and 12 months after completion of inpatient rehabilitation and cessation of testosterone supplementation. Therefore, this project will be completed within 3 years. Our short term goal (within 3 years) is to delineate the safety and efficacy of testosterone supplementation on rehabilitation outcomes in deconditioned older men. Our long range goal is to determine whether other hormones (e.g., combined testosterone and growth hormone) are helpful as an adjunct to traditional rehabilitation therapy in the care of older men
The invention belongs to the technical field of medical research, and particularly relates to an application of Nron and an expression promoter thereof in a vascular regulation medicament. The present invention mainly relates to: application of the Nron and/or the Nron expression promoter in preparing angiogenesis promoting medicines. Application of the Nron and/or the Nron expression promoter in preparing medicaments for preventing and treating angiogenesis disorders. Application of Nron and/or Nron expression promoter in preparing medicine for preventing and treating vascular diseases caused by ischemia is disclosed. Application of the Nron and/or the Nron expression promoter in preparing an expression promoter of vascular endothelial growth factors. Application of the Nron and/or the Nron expression promoter in preparing a preparation for promoting angiogenesis of atherosclerotic plaques. The invention provides a novel treatment scheme for some blood vessel related diseases, and particularly has a better promotion effect on promoting the formation of new blood vessels. And also provides some regulating reagents required by biological model making, and can better simulate some pathological conditions and the like in vitro.
FIELD: medicine, biochemistry. SUBSTANCE: blood plasma alcoholic precipitate-1 obtained by Cohn's schedule is dissolved in acetate buffer solution containing anticoagulating agent. Then cation-exchange sorbent is added to the precipitate solution up to complete fibrinogen binding and detergent and organic solvents are added to the solution. Then solution is incubated at 25-35 C for 8-24 h, sorbent is washed off from unbound protein and fibrinogen is eluted from sorbent with acetate buffer solution. Values pH and protein concentration in solution are corrected followed by sterilizing filtration, pouring and lyophilic drying the preparation obtained. EFFECT: improved method of producing, virologically safe fibrinogen preparation, decreased content of salt. 3 cl, 2 ex
Based on clinical trials, treatment with intravenous iron improves symptoms, exercise capacity, and may reduce HF hospitalizations in patients with HF and ID. On the contrary, treatment of ID with oral iron has no effect on exercise capacity. High hepcidin levels prevent oral intestinal absorption and blunt the response to oral iron administration. Sucrosomial iron (SI) consists of a nucleus of ferric pyrophosphate with an envelope of sucrose ester of fatty acids, which promotes intestinal absorption through paracellular and lymphatic routes, independent of hepcidin. In contrast with intravenous iron infusion, administration of oral iron may not promote oxidative stress, since the intestinal iron absorption prevent the formation of labile, non-transferrin bound, plasma iron.

The study will investigate the effect of oral SI supplementation on exercise capacity, assessed by six-minute walk test, and quality of life, assessed by Kansas City Cardiomyopathy Questionnaire, compared with placebo in patients with HF, a left ventricular ejection fraction (LVEF) \<50%. Iron deficiency was defined as transferrin saturation (TSAT) \<20%.
INTRODUCTION: The security crisis caused by the Islamic sect Boko Haram, coupled with arid climatic conditions and a context of poverty, has preyed on populations in the far north of Cameroon, exacerbating malnutrition rates among children under five years old. New evidence has shown that many children with moderate acute malnutrition (MAM) can be treated in their communities (CMAM) without having to be admitted to a health center or therapeutic feeding center. The purpose of our study was to identify factors that may lead to beneficiary dropout in a CMAM program in four health districts in the far north of Cameroon.
METHODS: A retrospective descriptive study of children who exited the CMAM program as lost to follow-up. Trained CHWs interviewed mothers in the households of children identified as lost to follow-up in the CMAM program using a questionnaire. The data were analyzed using STATA software. The confidence interval used was 95% and a P-value of 5%.
RESULTS: Seven hundred and ten children were identified as being lost to the CMAM program, 686 of whom were present in the households during the interviews. Boys were 40.20%; girls 59.79% and the median age was 19 months. In the post-CMAM period, boys (OR=0.64; p=0.018); children in Moulvoudaye health district (OR=0.32; p=0.0025), and households with ≥10 people were at lower risk of MAM. The risk of being MAM was higher in households located 6-10 km and -=10km from a health facility (OR=4.21, +0.0001). Vitamin A Supplementation (OR=0.37; p=0.0131) and dietary diversity (OR=0.60; p=0.0773) protected children from MAM. The main reasons for dropping out of the CMAM program cited by parents were that health personnel and CHWs had declared and discharged the child as cured (44.4%); mothers received information that the project was over (17.54%); and mothers had traveled (10.2%). Other reasons: parents not keeping appointments (4.5%); children not responding to treatment (4.8%); shortage of food supplies (3.1%); and the long distance between the distribution site and the household (5.6%) etc. Conclusion: Several children were discharged as dropouts while they were still active. These included discharge errors and those due to the end of the project. Distance, stock shortages, failure to keep appointments, parental relocation, and illnesses in children were all reasons for the high dropout rate. We recommend strengthening the quality of training for health personnel and CHWs on the CMAM protocol before implementation.
Patients will receive 5 fractions of 5 gray (Gy) or 6.6 Gy delivered over a five-day period based on whether or not they have received prior radiation therapy to the pancreatic region. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week. Initial patient positioning will be based on volumetric kV (cone-beam computerized tomography) imaging with shifts to bony anatomy as appropriate. Orthogonal kV/MV or kV/kV projection imaging will be used to verify the location of the fiducials prior to delivery of the first treatment beam. A secondary shift based on the location of fiducials may be utilized, as indicated by the position of the fiducials. For free-breathing treatments, kV fluoroscopic images should be obtained to confirm the anticipated position of these fiducials during the entire respiratory cycle. Active monitoring of treatment delivery accuracy will be accomplished using kV and/or MV projection imaging, either immediately before or during all (or a subset of) treatment fields. Patient-specific dosimetric quality assurance (QA) will be performed as per standard practice in the Department of Radiation Oncology, Indiana University School of Medicine.
Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.
OBJECTIVES: Spinal cord stimulation (SCS) is a surgical treatment for severe, chronic, neuropathic pain. It is based on one to two lead(s) implanted in the epidural space, stimulating the dorsal column. It has long been assumed that when deactivating SCS, there is a variable interval before the patient perceives the return of the pain, a phenomenon often termed echo or carryover effect. Although the carryover effect has been problematized as a source of error in crossover studies, no experimental investigation of the effect has been published. This open, prospective, international multicenter study aimed to systematically document, quantify, and investigate the carryover effect in SCS.
MATERIALS AND METHODS: Eligible patients with a beneficial effect from their SCS treatment were instructed to deactivate their SCS device in a home setting and to reactivate it when their pain returned. The primary outcome was duration of carryover time defined as the time interval from deactivation to reactivation. Central clinical parameters (age, sex, indication for SCS, SCS treatment details, pain score) were registered and correlated with carryover time using nonparametric tests (Mann-Whitney/Kruskal-Wallis) for categorical data and linear regression for continuous data.
RESULTS: In total, 158 patients were included in the analyses. A median carryover time of five hours was found (interquartile range 2.5;21 hours). Back pain as primary indication for SCS, high-frequency stimulation, and higher pain score at the time of deactivation were correlated with longer carryover time.
CONCLUSIONS: This study confirms the existence of the carryover effect and indicates a remarkably high degree of interindividual variation. The results suggest that the magnitude of carryover may be correlated to the nature of the pain condition and possibly stimulation paradigms.
CLINICAL TRIAL REGISTRATION: The Clinicaltrials.gov registration number for the study is NCT03386058.
In addition to amyloid beta plaques and neurofibrillary tangles, Alzheimer's disease (AD) has been associated with elevated iron in deep gray matter nuclei using quantitative susceptibility mapping (QSM). However, only a few studies have examined cortical iron, using more macroscopic approaches that cannot assess layer-specific differences. Here, we conducted column-based QSM analyses to assess whether AD-related increases in cortical iron vary in relation to layer-specific differences in the type and density of neurons. We obtained global and regional measures of positive (iron) and negative (myelin, protein aggregation) susceptibility from 22 adults with AD and 22 demographically matched healthy controls. Depth-wise analyses indicated that global susceptibility increased from the pial surface to the gray/white matter boundary, with a larger slope for positive susceptibility in the left hemisphere for adults with AD than controls. Curvature-based analyses indicated larger global susceptibility for adults with AD versus controls; the right hemisphere versus left; and gyri versus sulci. Region-of-interest analyses identified similar depth- and curvature-specific group differences, especially for temporo-parietal regions. Finding that iron accumulates in a topographically heterogenous manner across the cortical mantle may help explain the profound cognitive deterioration that differentiates AD from the slowing of general motor processes in healthy aging.
Dual antiplatelet therapy consisting of aspirin and a P2Y12 receptor antagonist is the cornerstone of treatment for prevention of thrombotic events in patients with acute coronary syndromes (ACS). Prasugrel, a third generation thienopyridine, is an orally administered prodrug that needs single-step hepatic biotransformation into its active metabolite to irreversibly block the P2Y12 receptor. Prasugrel has shown to be superior to clopidogrel, in adjunct to aspirin, in preventing recurrent ischemic events. Prasugrel is approved in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) at a dosage of 60 mg loading dose (LD) followed by 10 mg/day. However, a delay in the onset of its antiplatelet effects in this particular setting has been consistently shown. The STEMI setting is characterized by conditions, such as impaired absorption and hepatic metabolism, patients either intubated, in shock or unable to swallow, which may affect the pharmacoki¬netic and pharmacodynamic effects of orally administered antiplatelet drugs. The administration of clopidogrel and ticagrelor crushed tablets has been tested and a faster and greater bioavailability compared to the whole tablets has been observed. However, if the administration of a crushed prasugrel LD may overcome the above limitation is still unknown and represents the aim of our study. The proposed investigation will have a prospective, randomized, design in which STEMI patients undergoing primary PCI will be randomized to receive two different formulation of prasugrel LD (60 mg whole tablets and 60 mg crushed tablets). Pharmacodynamic testing will be performed at several time points to test our study hypothesis that crushed LD regiment will achieve more prompt and enhanced platelet inhibitory effects. This study will provide insights on the pharmacodynamic effects of crushed prasugrel LD and will help clinicians choose the most appropriate treatment to avoid complications related to inadequate platelet inhibition in the early phase of patients with STEMI undergoing primary PCI.